[1]
|
王凤燕, 张冬莹, 梁振宇, 等. 面向全科医生的《慢性阻塞性肺疾病诊治指南(2021年修订版)》解读[J]. 中国全科医学, 2021, 24(29): 3660-3663, 3677.
|
[2]
|
GOLD Exedutive Committee (2020) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.1wms.pdf
|
[3]
|
Vogelmeier, C.F., Criner, G.J., Martinez, F.J., et al. (2017) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. European Respiratory Journal, 49, Article ID: 1700214. https://doi.org/10.1183/13993003.00214-2017
|
[4]
|
(2019) Chronic Obstructive Pulmonary Disease in over 16 s: Diagnosis and Management. National Institute for Health and Care Excellence (NICE), London.
|
[5]
|
Wedzi-cha, J.A. and Wilkinson, T. (2006) Impact of Chronic Obstructive Pulmonary Disease Exacerbations on Patients and Payers. Proceedings of the American Thoracic Society, 3, 218-221. https://doi.org/10.1513/pats.200510-114SF
|
[6]
|
Donaldson, G.C., Seemungal, T.A., Bhowmik, A. and Wedzicha, J.A. (2002) Relationship between Exacerbation Frequency and Lung Function Decline in Chronic Obstructive Pulmonary Disease. Thorax, 57, 847-852.
https://doi.org/10.1136/thorax.57.10.847
|
[7]
|
Hurst, J.R., Vestbo, J., Anzueto, A., et al. (2010) Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. The New England Journal of Medicine, 363, 1128-1138. https://doi.org/10.1056/NEJMoa0909883
|
[8]
|
Donaldson, G.C., Hurst, J.R., Smith, C.J., et al. (2010) Increased Risk of Myocardial Infarction and Stroke following Exacerbation of COPD. Chest, 137, 1091-1097. https://doi.org/10.1378/chest.09-2029
|
[9]
|
Corlateanu, A., Covantev, S., Mathioudakis, A.G., et al. (2016) Preva-lence and Burden of Comorbidities in Chronic Obstructive Pulmonary Disease. Respiratory Investigation, 54, 387-396. https://doi.org/10.1016/j.resinv.2016.07.001
|
[10]
|
Kunisaki, K.M., Dransfield, M.T., Anderson, J.A., et al. (2018) Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 198, 51-57. https://doi.org/10.1164/rccm.201711-2239OC
|
[11]
|
姚汉玲, 陈德明, 李青林, 等. 穿琥宁注射液治疗慢性阻塞性肺病急性加重期效果及对IL-8、hs-CRP、TNF-α水平的影响[J]. 河北医科大学学报, 2020, 41(3): 268-271.
|
[12]
|
Woodhead, M., Blasi, F., Ewig, S., et al. (2011) Guidelines for the Management of Adult Lower Respir-atory Tract Infections—Full Version. Clinical Microbiology and Infection, 17, E1-E59.
https://doi.org/10.1111/j.1469-0691.2011.03672.x
|
[13]
|
陈闽江, 柳涛, 蔡柏蔷. 解读2011年成人下呼吸道感染的诊治指南(概述) [J]. 国际呼吸杂志, 2012, 32(16): 1201-1206.
|
[14]
|
中华医学会呼吸病学分会, 中华医学会儿科学分会. 流行性感冒抗病毒药物治疗与预防应用中国专家共识[J]. 中华医学杂志, 2016, 96(2): 85-90.
|
[15]
|
He, G., Massarella, J. and Ward, P. (1999) Clinical Pharmacokinetics of the Prodrug Oseltamivir and Its Active Metabolite Ro 64-0802. Clinical Pharmacokinetics, 37, 471-484. https://doi.org/10.2165/00003088-199937060-00003
|
[16]
|
Moscona, A. (2005) Neuraminidase Inhibitors for In-fluenza. The New England Journal of Medicine, 353, 1363-1373.
https://doi.org/10.1056/NEJMra050740
|
[17]
|
Oxford, J.S. (2000) Zanamivir (Glaxo Wellcome). IDrugs, 3, 447-459.
|
[18]
|
Su, C.P., Chan, K.A., Huang, C.T. and Fang, C.T. (2022) Inhaled Zanamivir vs Oral Oseltamivir to Pre-vent Influenza-Related Hospitalization or Death: A Nationwide Population-Based Quasi-Experimental Study. Clinical In-fectious Diseases, 75, 1273-1279. https://doi.org/10.1093/cid/ciac217
|
[19]
|
Venkatesan, P. (2022) GOLD Report: 2022 Update. The Lancet Respiratory Medicine, 10, E20.
https://doi.org/10.1016/S2213-2600(21)00561-0
|
[20]
|
Salama, K.S.M., Moazen, E.M., Elsawy, S.B., et al. (2023) Bacterial Species and Inflammatory Cell Variability in Respiratory Tracts of Patients with Chronic Obstructive Pulmonary Disease Exacerbation: A Multicentric Study. Infection and Drug Resistance, 16, 2107-2115. https://doi.org/10.2147/IDR.S402828
|
[21]
|
Mussema, A., Beyene, G. and Gashaw, M. (2022) Bacterial Isolates and Antibacterial Resistance Patterns in a Patient with Acute Exacerbation of Chronic Obstructive Pulmonary Disease in a Tertiary Teaching Hospital, Southwest Ethiopia. Canadian Journal of Infectious Diseases and Medical Microbiology, 2022, Article ID: 9709253.
https://doi.org/10.1155/2022/9709253
|
[22]
|
Seo, H., Sim, Y.S., Min, K.H., et al. (2022) The Relationship between Comorbidities and Microbiologic Findings in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Dis-ease. International Journal of Chronic Obstructive Pulmonary Disease, 20, 855-867. https://doi.org/10.2147/COPD.S360222
|
[23]
|
Millares, L. and Monso, E. (2022) The Microbiome in COPD: Emerging Potential for Microbiome-Targeted Interventions. International Journal of Chronic Obstructive Pulmonary Disease, 17, 1835-1845.
https://doi.org/10.2147/COPD.S371958
|
[24]
|
Ye, F., He, L.X., Cai, B.Q., et al. (2013) Spectrum and Antimicrobial Resistance of Common Pathogenic Bacteria Isolated from Patients with Acute Exacerbation of Chronic Obstructive Pul-monary Disease in Mainland of China. Chinese Medical Journal, 126, 2207-2214.
|
[25]
|
Liu, H.Y., Zhang, S.Y., Yang, W.Y., et al. (2017) Oropharyngeal and Sputum Microbiomes Are Similar following Exacerbation of Chronic Obstructive Pulmonary Disease. Frontiers in Microbiology, 8, Article 1163.
https://doi.org/10.3389/fmicb.2017.01163
|
[26]
|
Singh, D., Agusti, A., Anzueto, A., et al. (2019) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: The GOLD Science Committee Report 2019. European Respiratory Journal, 53, Article ID: 1900164. https://doi.org/10.1183/13993003.00164-2019
|
[27]
|
Wedzicha, J.A., Miravitlles, M., Hurst, J.R., et al. (2017) Management of COPD Exacerbations: A European Respiratory Society/American Thoracic Society Guideline. European Respiratory Journal, 49, Article ID: 1600791.
https://doi.org/10.1183/13993003.00791-2016
|
[28]
|
慢性阻塞性肺疾病急性加重抗感染治疗中国专家共识编写组. 慢性阻塞性肺疾病急性加重抗感染治疗中国专家共识[J]. 国际呼吸杂志, 2019, 39(17): 1281-1296.
|
[29]
|
王思思. 雾化吸入抗菌药物辅助治疗呼吸系统感染性疾病的有效性及安全性的Meta分析[D]: [硕士学位论文]. 天津: 天津医科大学, 2020.
|
[30]
|
Niederman, M.S., Alder, J., Bassetti, M., et al. (2020) Inhaled Amikacin Adjunctive to Intravenous Standard-of-Care Antibiotics in Mechanically Ventilated Patients with Gram-Negative Pneumonia (INHALE): A Double-Blind, Randomised, Placebo-Controlled, Phase 3, Superiority Trial. The Lancet Infectious Dis-eases, 20, 330-340.
https://doi.org/10.1016/S1473-3099(19)30574-2
|
[31]
|
Haworth, C.S., Bilton, D., Chalmers, J.D., et al. (2019) In-haled Liposomal Ciprofloxacin in Patients with Non-Cystic Fibrosis Bronchiectasis and Chronic Lung Infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): Two Phase 3, Randomised Controlled Trials. The Lancet Respira-tory Medicine, 7, 213-226.
https://doi.org/10.1016/S2213-2600(18)30427-2
|
[32]
|
Griffith, D.E., Eagle, G., Thomson, R., Aksamit, T.R., Ha-segawa, N., et al. (2018) Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. American Journal of Respiratory and Critical Care Medicine, 198, 1559-1569.
https://doi.org/10.1164/rccm.201807-1318OC
|
[33]
|
Mogayzel Jr, P.J., Naureckas, E.T., Robinson, K.A., et al. (2014) Cystic Fibrosis Foundation Pulmonary Guideline. Pharmacologic Approaches to Prevention and Eradication of Initial Pseudomonas aeruginosa Infection. Annals of the American Thoracic Society, 11, 1640-1650. https://doi.org/10.1513/AnnalsATS.201404-166OC
|
[34]
|
Dal Negro, R., Micheletto, C., Tognella, S., Visconti, M. and Turati, C. (2008) Tobramycin Nebulizer Solution in Severe COPD Patients Colonized with Pseudomonas aerugino-sa: Effects on Bronchial Inflammation. Advances in Therapy, 25, 1019-1030. https://doi.org/10.1007/s12325-008-0105-2
|
[35]
|
Naderi, N., Assayag, D., Mostafavi-Pour-Manshadi, S.M., et al. (2018) Long-Term Azithromycin Therapy to Reduce Acute Exacerbations in Patients with Severe Chronic Obstructive Pulmonary Disease. Respiratory Medicine, 138, 129-136. https://doi.org/10.1016/j.rmed.2018.03.035
|
[36]
|
Vermeersch, K., Gabrovska, M., Aumann, J., et al. (2019) Azithromycin during Acute Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization (BACE). A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. American Journal of Respiratory and Critical Care Medicine, 200, 857-868.
https://doi.org/10.1164/rccm.201901-0094OC
|
[37]
|
Ahmadian, S., Sin, D.D., Lynd, L., Harrison, M. and Sadatsa-favi, M. (2022) Benefit-Harm Analysis of Azithromycin for the Prevention of Acute Exacerbations of Chronic Obstruc-tive Pulmonary Disease. Thorax, 77, 1079-1087.
https://doi.org/10.1136/thoraxjnl-2021-217962
|
[38]
|
Cui, Y., Luo, L., Li, C., Chen, P. and Chen, Y. (2018) Long-Term Macrolide Treatment for the Prevention of Acute Exacerbations in COPD: A Systematic Review and Me-ta-Analysis. International Journal of Chronic Obstructive Pulmonary Disease, 13, 3813-3829. https://doi.org/10.2147/COPD.S181246
|
[39]
|
He, H.Y., Chang, S., Ding, L., et al. (2012) Significance of Asper-gillus spp. Isolation from Lower Respiratory Tract Samples for the Diagnosis and Prognosis of Invasive Pulmonary As-pergillosis in Chronic Obstructive Pulmonary Disease. Chinese Medical Journal, 125, 2973-2978.
|
[40]
|
严利华, 孙巧燕, 张叶辉. 不同剂量氟康唑对慢性阻塞性肺病急性加重期患者肺部真菌感染的效果观察[J]. 现代实用医学, 2021, 33(4): 523-524.
|
[41]
|
钟林岐. 不同剂量布地奈德雾化吸入对老年慢性阻塞性肺病急性加重期患者的治疗效果观察[J]. 北方药学, 2022, 19(7): 53-55.
|
[42]
|
Wu, L., Lan, N. and Yang, X. (2021) Effects of Empirical Gluco-corticoid Use on Severe Acute Exacerbation of COPD During Hospitalization. International Journal of Chronic Ob-structive Pulmonary Disease, 16, 2419-2431.
https://doi.org/10.2147/COPD.S300789
|
[43]
|
Li, L., Zhao, N., Ma, X., et al. (2021) Personalized Variable vs Fixed-Dose Systemic Corticosteroid Therapy in Hospitalized Patients with Acute Exacerbations of COPD: A Prospec-tive, Multicenter, Randomized, Open-Label Clinical Trial. Chest, 160, 1660-1669. https://doi.org/10.1016/j.chest.2021.05.024
|
[44]
|
Wang, J., Xu, G., Jin, H., et al. (2022) Ulinastatin Alleviates Rhabdomyolysis-Induced Acute Kidney Injury by Suppressing Inflammation and Apoptosis via Inhibiting TLR4/NF-κB Signaling Pathway. Inflammation, 45, 2052-2065.
https://doi.org/10.1007/s10753-022-01675-4
|
[45]
|
柴春艳, 刘娅萍, 王甜, 等. 乌司他丁辅助治疗70岁以上慢性阻塞性肺病急性加重期49例疗效及其对患者炎性因子影响研究[J]. 陕西医学杂志, 2018, 47(6): 790-792.
|
[46]
|
钱钧. 阿托伐他汀联合乌司他丁对慢性阻塞性肺病急性加重期的疗效及对氧化应激、肺功能的影响[J]. 数理医药学杂志, 2021, 34(1): 123-124.
|
[47]
|
Crocetti, L., Floresta, G., Cilibrizzi, A. and Giovannoni, M.P. (2022) An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022. Molecules, 27, Article 4964. https://doi.org/10.3390/molecules27154964
|
[48]
|
Buenestado, A., Grassin-Delyle, S., Guitard, F., et al. (2012) Roflumilast Inhibits the Release of Chemokines and TNF-α from Human Lung Macrophages Stimulated with Lipopoly-saccharide. British Journal of Pharmacology, 165, 1877-1890. https://doi.org/10.1111/j.1476-5381.2011.01667.x
|
[49]
|
Hatzelmann, A., Morcillo, E.J., Lungarella, G., et al. (2010) The Preclinical Pharmacology of Roflumilast—A Selective, Oral Phosphodiesterase 4 Inhibitor in Development for Chronic Obstructive Pulmonary Disease. Pulmonary Pharmacology & Therapeutics, 23, 235-256. https://doi.org/10.1016/j.pupt.2010.03.011
|
[50]
|
王惠芳, 王有志, 支运宝, 等. 磷酸二酯酶4抑制剂临床及安全性研究进展[J]. 药学学报, 2023, 58(9): 2601-2609.
https://kns.cnki.net/kcms2/article/abstract?v=IUBLoWpfHZFh_7R-SImaB9DyDqVRZtfgL9tIve8_GsAqsWYesYUe5etvl9FivN
Ppau0_lHg6oVxLXJcq5G1bcH1_vB5pRJW0i2_LGNtS8JKm
UM8XMLmsogJV5b0oFgqG&uniplatform=NZKPT&flag=copy
|
[51]
|
Wedzicha, J.A., Calverley, P.M. and Rabe, K.F. (2016) Roflumilast: A Review of Its Use in the Treatment of COPD. International Journal of Chronic Obstructive Pulmonary Disease, 11, 81-90. https://doi.org/10.2147/COPD.S89849
|
[52]
|
Martinez, F.J., Calverley, P.M., Goehring, U.M., et al. (2015) Effect of Roflumilast on Exacerbations in Patients with Severe Chronic Obstructive Pulmonary Disease Uncontrolled by Com-bination Therapy (REACT): A Multicentre Randomised Controlled Trial. Lancet, 385, 857-866. https://doi.org/10.1016/S0140-6736(14)62410-7
|
[53]
|
郎丽娟. 浅谈吸入用乙酰半胱氨酸溶液在慢性阻塞性肺病急性加重中的治疗作用[J]. 智慧健康, 2022, 8(26): 27-30, 35.
|
[54]
|
梁蔚繁. 盐酸氨溴索联合噻托溴铵治疗急性期老年慢性阻塞性肺疾病的临床效果[J]. 中国医药, 2020, 15(6): 864-868.
|
[55]
|
宫姝宁, 张玲燕, 王颖. 盐酸氨溴索治疗老年慢性阻塞性肺疾病合并肺部感染的临床效果及安全性[J]. 临床合理用药, 2023, 16(8): 62-65.
|
[56]
|
袁琪, 林勇. 福多司坦对慢性阻塞性肺病急性加重期患者预后的影响[J]. 临床肺科杂志, 2016, 21(10): 1802-1804.
|
[57]
|
马康, 聂智品. 硫酸镁治疗慢性阻塞性肺疾病的Meta分析[J]. 临床荟萃, 2016, 31(12): 1362-1369.
|
[58]
|
Branson, R.D. (2018) Oxygen Therapy in COPD. Respiratory Care, 63, 734-748.
https://doi.org/10.4187/respcare.06312
|
[59]
|
Zheng, Z.G., Sun, W.Z., Hu, J.Y., et al. (2021) Hydrogen/Oxygen Therapy for the Treatment of an Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Results of a Multicenter, Randomized, Double-Blind, Parallel-Group Controlled Trial. Respiratory Research, 22, Article No. 149. https://doi.org/10.1186/s12931-021-01740-w
|
[60]
|
Sandau, C., Hansen, E.F., Ringbæk, T.J., et al. (2023) Auto-mated Oxygen Administration Alleviates Dyspnea in Patients Admitted with Acute Exacerbation of COPD: A Random-ized Controlled Trial. International Journal of Chronic Obstructive Pulmonary Disease, 18, 599-614. https://doi.org/10.2147/COPD.S397782
|
[61]
|
张小艳, 李清. 无创通气对慢性阻塞性肺病急性加重期疗效的影响分析[J]. 中国社区医师, 2021, 37(3): 94-95.
|